The institute said the biosamples encompass a variety of cancer-related mutations available for preclinical drug development and as reference samples for labs that are certified to comply with Clinical Laboratory Improvement Amendments.

BioChain now offers ready-to-use, NGS-characterized tissue samples for BRCA1, BRCA2, microsatellite instability, human papilloma virus, epidermal growth factor receptor, and KRAS, the institute said. It is developing the new mutation-specific biosamples in response to the growing need expressed by researchers for these samples.